
Novo Nordisk CEO Sounds Alarm on Compounded Semaglutide Risks Amid Rising Deaths
The CEO of Novo Nordisk raises concerns about compounded semaglutide’s potentially fatal side effects, citing FDA reports of ten fatalities. Novo Nordisk highlights patient safety issues due to the unregulated and increasing popularity of compounded formulations. Novo Nordisk CEO Lars Fruergaard Jorgensen issued a severe warning to American consumers regarding compounded forms of semaglutide, a…